New Investment Fund Targeting Drug Development at the University of Pittsburgh
from Pittsburgh Post-Gazette
University of Pittsburgh Chancellor Patrick Gallagher's efforts to hotwire the region's fledgling life sciences industry is getting a spark from a new seed capital fund targeted to helping develop new medications. The Pittsburgh Revolution Fund is soliciting $200 million, which will be made available in the form of investments in drug research teams with the idea of spinning out companies, said Bill Newlin, chairman, Newlin Investment Co., a seed-stage investment firm in Sewickley.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063